Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | G6PD | P11413 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2843289 | 0.84 | KDM4E (0.37) | TP53ALDH1A1SMN1; SMN2SLC6A4HRH1 | |
| SCHEMBL2843705 | 0.80 | CBFB (0.49) | TP53G6PDALDH1A1SMN1; SMN2SLC6A4 | |
| SCHEMBL2844385 | 0.79 | HSD17B10 (0.46) | TP53SMN1; SMN2POLB | |
| SCHEMBL2849291 | 0.79 | POLB (0.41) | SMN1; SMN2POLBPARP1 | |
| SCHEMBL9306439 | 0.72 | DAO (0.46) | ALDH1A1SMN1; SMN2DRD4DAO | |
| SCHEMBL1884521 | 0.72 | POLB (0.72) | SMN1; SMN2POLB | |
| SCHEMBL9306376 | 0.72 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2PTGS2DRD4DAO | |
| SCHEMBL2735452 | 0.72 | TLR8 (0.46) | ALDH1A1SMN1; SMN2DAO | |
| SCHEMBL2310462 | 0.68 | HSD17B10 (0.44) | TP53ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL24712708 | 0.68 | HRH1 (0.55) | TP53ALDH1A1SLC6A4HRH1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2152670-B1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-12-25 | — | — | EP | disclosed |
| US-8202885-B2 | Bridged six-membered ring compounds | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-06-19 | — | — | US | disclosed |
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130545-A1 | BRIDGED SIX-MEMBERED RING COMPOUNDS | CACNA1E, CACNA1B, CACNA1A | TP53 4168/4885G6PD 3380/4885ALDH1A1 1834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.